Stay updated with breaking news from Chengbin Wu. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
SHANGHAI & SUZHOU, China--(BUSINESS WIRE)--EpimAb Biotherapeutics, a clinical-stage biotechnology company specializing in bispecific antibody development, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for a Phase Ib/II study in patients wi...
EpimAb Biotherapeutics, a clinical-stage biotechnology company specializing in bispecific antibody development, today announced that the U.S. Food and
SHANGHAI & SUZHOU, China--(BUSINESS WIRE)--EpimAb Biotherapeutics, a clinical stage biotech company specializing in bispecific antibodies, today announced the appointment of Andrew X. Zhu, M.D., Ph.D., to the company’s Scientific Advisory Board. Dr. Zhu is internationally recognized as a leading authority in hepatoc...
Published: May 27, 2021 SHANGHAI--(BUSINESS WIRE)-- EpimAb Biotherapeutics, a clinical stage biotech company specializing in bispecific antibodies, today announced the appointment of Jerry Su, Ph.D. as the Chief Technology Officer of EpimAb. Dr. Su joined EpimAb in December 2019 as Senior VP, CMC and led the completion of EpimAb’s early CMC development facility in Suzhou BioBay. In this newly created role, Dr. Su will continue to oversee the company’s CMC development and manufacturing operations. “Since he joined EpimAb, Jerry contributed significantly to the organizational growth o...